CINCINNATI--(BUSINESS WIRE)--Camargo Pharmaceutical Services, the 505(b)(2) experts, is teaming with XenoTech, a leading contract research organization in the drug metabolism field, to present a webinar March 21 for drug developers who want to learn how to use the 505(b)(2) pathway to leverage preclinical studies to obtain regulatory approval faster and at a reduced cost. The webinar, “Utilizing the 505(b)(2) Pathway to Streamline and Accelerate a Drug Development Plan,” will explain how to identify potential candidates and the best process to obtain approval from the U.S. Food and Drug Administration. Andrea Hubbel, Camargo preclinical project manager, and Mark Horrigan, XenoTech senior mass spectrometry specialist and qualitative analytical chemistry group leader, will discuss how their team successfully developed an initial development plan using the 505(b)(2) program for a drug candidate designated for cardiovascular disease.
